Heart failure (HF) remains a leading cause of morbidity and mortality, but timely initiation and optimization of guideline-directed medical therapy (GDMT) can meaningfully improve outcomes. In patients with HFrEF, comprehensive quadruple therapy—including a RAAS inhibitor, beta-blocker, mineralocorticoid receptor antagonist (MRA), and SGLT2 inhibitor—can reduce mortality by over 70%. Trials such as STRONG-HF have demonstrated that early, in-hospital or post-discharge uptitration lowers rehospitalization and death rates.
Comorbidities—particularly the cardiovascular–kidney–metabolic overlap—complicate management but highlight the need for individualized care. RAAS inhibitors reduce intraglomerular pressure and proteinuria. SGLT2 inhibitors decrease glucose reabsorption and myocardial stress, benefiting patients with or without diabetes. Nonsteroidal MRAs may also reduce renal decline and cardiovascular events in patients with type 2 diabetes and CKD. Therapy decisions must consider renal function, potassium levels, and blood pressure.
Risk stratification with tools such as LVEF, NT-proBNP, and NYHA class can guide therapy intensity and follow-up. For example, elevated NT-proBNP levels post-GDMT initiation are prognostic and can help refine monitoring strategies.
Multidisciplinary HF programs—including pharmacist-led titration, digital tools, and remote monitoring—can reduce readmissions by up to 40% and mortality by 25%.
How can your team best use pharmacist-led or digital titration to accelerate GDMT optimization in HFrEF? What strategies have been effective in overcoming therapeutic inertia and improving adherence?
Share
-
Lisa Canter1wThese medications are sometimes expensive and the regimens can be complex for patients. A call from a pharmacist to the patient once they are home to confirm what they are taking ( sometimes we find out at first post hospital visit patient continued to take prior meds along with new ones ) and to make sure they didn’t have cost barriers -
Sherri Hernandez, Dr.Malik1wPatients with HFrEF are complex. Yes it takes a team approach. All these medications require close follow up with renal function monitoring not to mention the cost and prior authorization process.
-
Paul Albert2wIt's important to not allow digital logarithms to overtake individual contact with a patient and common sense. In my experience, the algorithm does not always fit. The individual patients needs, there is danger in treating just a number and not an individual. So I think we need to be cautious in such integration